Search Results for: "genentech v amgen"

BPCIA Litigation Roundup (Fall 2017)

Below is our fall update on the U.S. patent litigations concerning proposed or approved biosimilar products. For additional details, please consult our BPCIA Litigation Summary Chart or our previous quarterly updates (Summer 2016, Fall 2016, Midwinter 2017, Spring 2017, Summer 2017).

Read More

Biosimilar Litigation Updates

Below is an update on recent developments in several litigations involving biosimilar products. AbbVie v. Boehringer Ingelheim (adalimumab):  On October 23, the parties filed a joint status report.  Among other things, the parties offered their competing proposals for the schedule and the scope of discovery, including limits on the number…

Read More

Genentech Files A Complaint Against Amgen in Delaware Regarding MVASI® (bevacizumab-awwb)

We previously reported that on October 6, 2017, Amgen filed a declaratory judgment action against Genentech regarding Amgen’s recently approved biosimilar of Avastin® (bevacizumab-awwb). On the same day, Genentech filed a complaint in the District of Delaware, Civil Action No. 1:17cv1407.  While the complaint was filed under seal, according to a motion to transfer…

Read More

BPCIA Litigation Roundup (Spring 2017)

Below is our spring update on the U.S. patent litigations concerning proposed or approved biosimilar products. For additional details, please consult our BPCIA Litigation Summary Chart or our previous quarterly updates (Summer 2016, Fall 2016, Midwinter 2017).

Read More

Delaware Court Declines to Enter "Judgment" in Genentech v. Amgen

We have previously reported on letters submitted by Genentech and Amgen to the District of Delaware regarding Genentech’s decision not to file an amended complaint.  In its letter, Genentech requested entry of judgment without prejudice, which Amgen argued was unnecessary given the court’s prior order of dismissal without prejudice.  This morning,…

Read More

Genentech Will Not File Amended Complaint in Case Against Amgen

As we previously reported, the District of Delaware granted a motion to dismiss by Amgen in Genentech v. Amgen, finding a lack of subject matter jurisdiction over Genentech’s declaratory judgment complaint under the Federal Circuit’s holding in Amgen v. Sandoz.  The court granted the motion with leave for Genentech to amend its complaint…

Read More

Delaware District Court Dismisses Genentech v. Amgen

As we previously reported, yesterday Judge Sleet, United States District Court for the District of Delaware, heard arguments on Amgen’s motion to dismiss in Genentech v. Sandoz.  The court orally granted Amgen’s motion under the Federal Circuit’s holding in Amgen v. Sandoz.  The court dismissed Genentech’s complaint in its entirety without prejudice and with leave to amend…

Read More